Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 9/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | THRA | P10827 | 6/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20150211 | 0.78 | THRB (0.39) | LMNAMAPTHTTTHRBMEN1 | |
| SCHEMBL20150201 | 0.70 | TYK2 (0.44) | LMNAMAPTHTTTHRBVCAM1 | |
| SCHEMBL20150215 | 0.68 | THRB (0.39) | LMNAMAPTHTTTHRBMEN1 | |
| SCHEMBL20150212 | 0.68 | ERN1 (0.45) | LMNAMAPTHTTTHRBMEN1 | |
| SCHEMBL20150270 | 0.67 | ATM (0.61) | LMNATHRBMEN1KMT2AVCAM1 | |
| SCHEMBL30908542 | 0.65 | TSHR (0.60) | THRBMEN1KMT2AVCAM1CCR2 | |
| SCHEMBL15703077 | 0.65 | TSHR (0.60) | THRBMEN1KMT2AVCAM1CCR2 | |
| SCHEMBL20136292 | 0.64 | CA1 (0.40) | THRBMEN1KMT2AVCAM1CCR2 | |
| SCHEMBL17785771 | 0.64 | VCAM1 (0.44) | THRBMEN1KMT2AVCAM1POLB | |
| SCHEMBL11879430 | 0.64 | VCAM1 (0.48) | LMNAMAPTTHRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | LMNA 2078/4885MAPT 1236/4885HTT 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.